333 research outputs found

    Coupling Between Thermal Oscillations in the Surface of a Micro-Cylinder and Vortex Shedding

    Get PDF
    his article studies the coupling between prescribed thermal oscillations in the surface of a micro-cylinder and vortex shedding. We deal with the unsteady, laminar, compressible flow regime where the aerodynamics forces have a periodic behavior. It is shown that appropriate spatial and time-dependent temperature oscillations on the surface of the micro-cylinder create a resonance that controls the amplitude and frequency of both lift and drag coefficients. In practice, what we study is a mechanism to modulate the amplitude and frequency of mechanical loads of aerodynamics origin in a micro-structure by using surface temperature fluctuations as the control parameter

    Hybrid model of the plasma accelerator with open walls and closed electron drift

    No full text
    The original approach to use Hall-type plasma accelerators with closed electron drift and open walls for production converging towards axis accelerating ion beam describes here. The two-dimensional theoretical hybrid model was created. The performed computer modeling showed that in high-current mode the potential drop forms at the axis. This effect can be used for self consistent accelerating the ions moving toward the system center and then along the axis in both directions.Описано ΠΎΡ€ΠΈΠ³Ρ–Π½Π°Π»ΡŒΠ½ΠΈΠΉ ΠΏΡ–Π΄Ρ…Ρ–Π΄ ΠΊ Π²ΠΈΠΊΠΎΡ€ΠΈΡΡ‚Π°Π½Π½ΡŽ ΠΏΠ»Π°Π·ΠΌΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡ€ΠΈΡΠΊΠΎΡ€ΡŽΠ²Π°Ρ‡Π° Π· Π²Ρ–Π΄ΠΊΡ€ΠΈΡ‚ΠΈΠΌΠΈ стінками Ρ‚Π° Π·Π°ΠΌΠΊΠ½ΡƒΡ‚ΠΈΠΌ Π΄Ρ€Π΅ΠΉΡ„ΠΎΠΌ Π΅Π»Π΅ΠΊΡ‚Ρ€ΠΎΠ½Ρ–Π² для створСння Π΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΈΡ… пристроїв задля застосування Π² сучасних тСхнологіях, Ρ‚Π°ΠΊΠΈΡ… як модифікація ΠΏΠΎΠ²Π΅Ρ€Ρ…ΠΎΠ½ΡŒ, кСрування ΠΏΡƒΡ‡ΠΊΠ°ΠΌΠΈ зарядТСних частинок Ρ‚Π° як ΠΏΡ€ΠΎΡ‚ΠΎΡ‚ΠΈΠΏ ΠΌΠ°Π½Π΅Π²Ρ€ΠΎΠ²ΠΈΡ… космічних Ρ–ΠΎΠ½Π½ΠΈΡ… Π΄Π²ΠΈΠ³ΡƒΠ½Ρ–Π². НавСдСно Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΈ Π΅ΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½ΠΈΡ… Π΄ΠΎΡΠ»Ρ–Π΄ΠΆΠ΅Π½ΡŒ. ΠŸΠΎΠ±ΡƒΠ΄ΠΎΠ²Π°Π½ΠΎ Π΄Π²ΠΎΠ²ΠΈΠΌΡ–Ρ€Π½Ρƒ Π³Ρ–Π±Ρ€ΠΈΠ΄Π½Ρƒ модСль Ρ– прСдставлСно Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΈ Ρ‡ΠΈΡΠ΅Π»ΡŒΠ½ΠΎΠ³ΠΎ модСлювання.Oписан ΠΎΡ€ΠΈΠ³ΠΈΠ½Π°Π»ΡŒΠ½Ρ‹ΠΉ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ ΠΊ использованию ΠΏΠ»Π°Π·ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ускоритСля с ΠΎΡ‚ΠΊΡ€Ρ‹Ρ‚Ρ‹ΠΌΠΈ стСнками ΠΈ Π·Π°ΠΌΠΊΠ½ΡƒΡ‚Ρ‹ΠΌ Π΄Ρ€Π΅ΠΉΡ„ΠΎΠΌ элСктронов для создания эффСктивного устройства, ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠ΅ ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ использовано Π² соврСмСнных тСхнологиях, Π² частности для ΠΌΠΎΠ΄ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΈ повСрхностСй, управлСния ΠΏΡƒΡ‡ΠΊΠ°ΠΌΠΈ заряТСнных частиц, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΊΠ°ΠΊ ΠΏΡ€ΠΎΡ‚ΠΎΡ‚ΠΈΠΏ ΠΌΠ°Π»ΠΎΠ³Π°Π±Π°Ρ€ΠΈΡ‚Π½ΠΎΠ³ΠΎ Ρ€Π°ΠΊΠ΅Ρ‚Π½ΠΎΠ³ΠΎ двигатСля. ΠŸΡ€ΠΈΠ²Π΅Π΄Π΅Π½Ρ‹ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΡΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований. ΠŸΠΎΡΡ‚Ρ€ΠΎΠ΅Π½Π° двумСрная гибридная модСль ΠΈ прСдставлСны Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ числСнного модСлирования

    Final-state interactions in the response of nuclear matter

    Get PDF
    Final-state interactions in the response of a many-body system to an external probe delivering large momentum are normally described using the eikonal approximation, for the trajectory of the struck particle, and the frozen approximation, for the positions of the spectators. We propose a generalization of this scheme, in which the initial momentum of the struck particle is explicitly taken into account. Numerical calculations of the nuclear matter response at 1 <∣q∣<< |{\bf q}| < 2 GeV/c show that the inclusion of this momentum dependence leads to a sizable effect in the low energy tail. Possible implications for the analysis of existing electron-nucleus scattering data are discussed.Comment: 21 pages, 4 figure

    Sensitivity of Cross Sections for Elastic Nucleus-Nucleus Scattering to Halo Nucleus Density Distributions

    Full text link
    In order to clear up the sensitivity of the nucleus-nucleus scattering to the nuclear matter distributions of exotic halo nuclei, we have calculated differential cross sections for elastic scattering of the 6^6He and 11^{11}Li nuclei on several nuclear targets at the energy of 0.8 GeV/nucleon with different assumed nuclear density distributions in 6^6He and 11^{11}Li.Comment: 10 pages, 7 figures. Submitted to Proceedings of the 61 International Conference "Nucleus-2011" on the Problems of the Nuclear Spectroscopy and the Atomic Nuclear Structure, Sarov Nijzegorodskaya district, October 10-14, 201

    Effect of lithium borate coating on the electrochemical properties of LiCoO2 electrode for lithium-ion batteries

    Get PDF
    The effect of a protective coating of fused lithium borate, Li3BO3, on the physicochemical and electrochemical characteristics of LiCoO2 has been studied. A cathode material produced by the SCS method using binary organic fuel, glycine and citric acid. The influence of the experiment conditions on the morphology, crystal structure and specific surface of lithium cobaltite was studied. Electrochemical testing of LiCoO2βˆ™nLi3BO3 samples, nΒ =Β 5 and 7 mass %, has been performed in the cathode Li|Li+-electrolyte|LiCoO2βˆ™nLi3BO3 half-cell using 1M LiPF6 in EC/DMC mixture (1:1) as electrolyte in the 2.7-4.3 V range at normalized discharge current Π‘/10, Π‘/5, Π‘/2. The maximal initial discharge capacity of 185 mAh/g was detected for the samples with 5 mass % Li3BO3. The coulomb efficiency of optimal materials in the 40th cycle was 99.1%

    Π₯Ρ€ΠΎΠΌΠΎΠ³Π΅Π½Π½Ρ‹ΠΉ Π°Π½Ρ‚ΠΈΠ₯Π°-тСст: ΡΠΎΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄Ρƒ Π΅Π΄ΠΈΠ½ΠΈΡ†Π°ΠΌΠΈ активности Π³Π΅ΠΏΠ°Ρ€ΠΈΠ½Π° ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠ΅ΠΉ апиксабана ΠΈ ривароксабана

    Get PDF
    Introduction. The direct oral anticoagulants (DOC) therapy does not require alaboratory control; however, it may be required to determine the anticoagulationlevel to choose a treatment strategy if alarge bleeding is developing or emergency surgery is needed.The objective of this experimental study was to investigate the relationship between the residual factor Xa (FXa) activity, anti-Xa activity units oflow molecular weight heparins (LMWH), and the apixaban and rivaroxaban plasma concentrations in a chromogenic anti-Xa assay.Material and methods. Concentrated DOC solutions were prepared by extracting apixaban and rivaroxaban from crushed tablets using methanol and dimethyl sulfoxide, respectively. The resulting solutions were added to the donor plasma pool until final inhibitor concentrations are achieved in the range from 10 to 100 ng/ml plasma. Anti-Xa activity was determined using an STA-compact analyser and the Liquid anti-Xa reagent kit, an analysis protocol, and calibrators designed to control the LMWH therapy. The effect on the thrombin formation dynamics was investigated using the thrombin generation test (TGT) and the PPR reagent as a trigger (final concentrations of tissue factor are 5 pM, and those of phospholipids are 4 ΞΌM). TGT curves were analysed using the Thrombinoscope program.Results. It was shown that in the anti-Xa activity test version designed to control the LMWH therapy, there is a high correlation (R2 &gt; 0.98) between thelogarithm of the residual factor Xa activity and the content of apixaban and rivaroxaban in the range from 10 to 80 ng/ml. Rivaroxaban shows about 1.5 times more anti-Xa activity than apixaban at equal concentrations. It was also shown that apixaban and rivaroxaban at doses equal both in concentration and in anti-Xa activity differ in their effect on the thrombin formation dynamics and thrombin inactivation in the TGT.Conclusion. In the LMWH anti-Xa activity test version, the measured range of apixaban and rivaroxaban includes 30 ng/ml and 50 ng/ ml concentrations taken as β€œcut-off points” to determine the treatment tactics in emergency cases. However, thelack of certified DOC calibratorslimits the use of this test in clinical practice.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ВСрапия прямыми ΠΎΡ€Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ антикоагулянтами (ПОАК) Π½Π΅ Ρ‚Ρ€Π΅Π±ΡƒΠ΅Ρ‚ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½ΠΎΠ³ΠΎ контроля, ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ опрСдСлСния уровня антикоагуляции ΠΌΠΎΠΆΠ΅Ρ‚ ΠΏΠΎΡ‚Ρ€Π΅Π±ΠΎΠ²Π°Ρ‚ΡŒΡΡ для Π²Ρ‹Π±ΠΎΡ€Π° Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ лСчСния ΠΏΡ€ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ большого кровотСчСния ΠΈΠ»ΠΈ нСобходимости выполнСния срочной ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ.ЦСлью этого ΡΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ исслСдования являлось ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ взаимосвязи ΠΌΠ΅ΠΆΠ΄Ρƒ остаточной Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° Π₯Π° (Π€Π₯Π°), Π΅Π΄ΠΈΠ½ΠΈΡ†Π°ΠΌΠΈ Π°Π½Ρ‚ΠΈΠ₯Π°-активности Π³Π΅ΠΏΠ°Ρ€ΠΈΠ½ΠΎΠ² Π½ΠΈΠ·ΠΊΠΎΠΉ молСкулярной массы (Π“ΠΠœΠœ) ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠ΅ΠΉ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ апиксабана ΠΈ ривароксабана Π² Ρ…Ρ€ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΠΌ тСстС Π½Π° Π°Π½Ρ‚ΠΈΠ₯Π°-Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΏΠ»Π°Π·ΠΌΡ‹.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠšΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Π΅ растворы ПОАК Π±Ρ‹Π»ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ экстракциСй апиксабана ΠΌΠ΅Ρ‚Π°Π½ΠΎΠ»ΠΎΠΌ, Π° ривароксабана Π΄ΠΈΠΌΠ΅Ρ‚ΠΈΠ»ΡΡƒΠ»ΡŒΡ„ΠΎΠΊΡΠΈΠ΄ΠΎΠΌ ΠΈΠ· ΠΈΠ·ΠΌΠ΅Π»ΡŒΡ‡Π΅Π½Π½Ρ‹Ρ… Ρ‚Π°Π±Π»Π΅Ρ‚ΠΎΠΊ. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ растворы добавляли ΠΊ ΠΏΡƒΠ»Ρƒ ΠΏΠ»Π°Π·ΠΌ Π΄ΠΎΠ½ΠΎΡ€ΠΎΠ² Π΄ΠΎ ΠΊΠΎΠ½Π΅Ρ‡Π½Ρ‹Ρ… ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΉ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ‚ΠΎΡ€ΠΎΠ² Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΎΡ‚ 10 Π΄ΠΎ 100 Π½Π³/ΠΌΠ» ΠΏΠ»Π°Π·ΠΌΡ‹. ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°Π½Ρ‚ΠΈΠ₯Π°-активности Π²Ρ‹ΠΏΠΎΠ»Π½ΡΠ»ΠΎΡΡŒ Π½Π° Π°Π½Π°Π»ΠΈΠ·Π°Ρ‚ΠΎΡ€Π΅ STA-compact с использованиСм Π½Π°Π±ΠΎΡ€Π° Ρ€Π΅Π°ΠΊΡ‚ΠΈΠ²ΠΎΠ² Liquid anti-Xa, ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»Π° Π°Π½Π°Π»ΠΈΠ·Π° ΠΈ ΠΊΠ°Π»ΠΈΠ±Ρ€Π°Ρ‚ΠΎΡ€ΠΎΠ², ΠΏΡ€Π΅Π΄Π½Π°Π·Π½Π°Ρ‡Π΅Π½Π½Ρ‹Ρ… для контроля Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π“ΠΠœΠœ. ВлияниС Π½Π° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ образования Ρ‚Ρ€ΠΎΠΌΠ±ΠΈΠ½Π° исслСдовали с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ тСста Π³Π΅Π½Π΅Ρ€Π°Ρ†ΠΈΠΈ Ρ‚Ρ€ΠΎΠΌΠ±ΠΈΠ½Π° (Π’Π“Π’) с использованиСм Π² качСствС Ρ‚Ρ€ΠΈΠ³Π³Π΅Ρ€Π° PPR-reagent (ΠΊΠΎΠ½Π΅Ρ‡Π½Ρ‹Π΅ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ Ρ‚ΠΊΠ°Π½Π΅Π²ΠΎΠ³ΠΎ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° - 5 пМ, Π° фосфолипидов - 4 мкМ). ΠšΡ€ΠΈΠ²Ρ‹Π΅ Π’Π“Π’ Π°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π»ΠΈ с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΡ‹ Thrombinoscope.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Показано, Ρ‡Ρ‚ΠΎ Π² Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Π΅ тСста Π½Π° Π°Π½Ρ‚ΠΈΠ₯Π°-Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ, ΠΏΡ€Π΅Π΄Π½Π°Π·Π½Π°Ρ‡Π΅Π½Π½ΠΎΠΌ для контроля Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π“ΠΠœΠœ, Π½Π°Π±Π»ΡŽΠ΄Π°Π΅Ρ‚ΡΡ высокая коррСляция (R2 &gt; 0,98) ΠΌΠ΅ΠΆΠ΄Ρƒ Π»ΠΎΠ³Π°Ρ€ΠΈΡ„ΠΌΠΎΠΌ остаточной активности Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° Π₯Π° ΠΈ содСрТаниСм апиксабана ΠΈ ривароксабана Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΎΡ‚ 10 Π΄ΠΎ 80 Π½Π³/ΠΌΠ». Π’ Ρ€Π°Π²Π½Ρ‹Ρ… концСнтрациях ривароксабан проявляСт ΠΏΡ€ΠΈΠΌΠ΅Ρ€Π½ΠΎ Π² 1,5 Ρ€Π°Π·Π° Π±ΠΎΠ»ΡŒΡˆΡƒΡŽ Π°Π½Ρ‚ΠΈΠ₯Π°-Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ, Ρ‡Π΅ΠΌ апиксабан. Показано Ρ‚Π°ΠΊΠΆΠ΅, Ρ‡Ρ‚ΠΎ апиксабан ΠΈ ривароксабан Π² Π΄ΠΎΠ·Π°Ρ…, Ρ€Π°Π²Π½Ρ‹Ρ… ΠΊΠ°ΠΊ ΠΏΠΎ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ, Ρ‚Π°ΠΊ ΠΈ ΠΏΠΎ Π°Π½Ρ‚ΠΈΠ₯Π°-активности Ρ€Π°Π·Π»ΠΈΡ‡Π°ΡŽΡ‚ΡΡ ΠΏΠΎ влиянию Π½Π° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ образования ΠΈ ΠΈΠ½Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠΈ Ρ‚Ρ€ΠΎΠΌΠ±ΠΈΠ½Π° Π² Π’Π“Π’.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π’ Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Π΅ тСста Π½Π° Π°Π½Ρ‚ΠΈΠ₯Π°-Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π“ΠΠœΠœ измСряСмый Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½ апиксабана ΠΈ ривароксабана Π²ΠΊΠ»ΡŽΡ‡Π°Π΅Ρ‚ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ 30 Π½Π³/ΠΌΠ» ΠΈ 50 Π½Π³/ΠΌΠ», принятыС Π² качСствС Β«ΠΎΡ‚Ρ€Π΅Π·Π½Ρ‹Ρ… Ρ‚ΠΎΡ‡Π΅ΠΊΒ» для опрСдСлСния Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ лСчСния Π² экстрСнных случаях. Однако отсутствиС сСртифицированных ΠΊΠ°Π»ΠΈΠ±Ρ€Π°Ρ‚ΠΎΡ€ΠΎΠ² ПОАК ΠΎΠ³Ρ€Π°Π½ΠΈΡ‡ΠΈΠ²Π°Π΅Ρ‚ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ использования этого тСста Π² клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅
    • …
    corecore